ViewRay

ViewRay R&D Expenses

The Research & Development Expenses of ViewRay (VRAYQ) as of Oct 10, 2026 is 32.43 M USD. In the previous year, Research & Development Expenses was 31.85 M USD — a change of 1.83% (higher).

R&D Expenses

32.43 MUSD

YoY

1.83%

Last updated:

Research & Development Expenses of ViewRay is 2022 32.43 M USD. Research & Development Expenses of ViewRay was 2021 31.85 M USD. It decreases by 1.83% higher compared to the previous year.

The ViewRay R&D Expenses history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

R&D Expenses
Date
R&D Expenses
Jan 1, 2015
10.45 M USD
Jan 1, 2016
11.44 M USD
Jan 1, 2017
14.71 M USD
Jan 1, 2018
16.52 M USD
Jan 1, 2019
19.10 M USD
Jan 1, 2020
25.01 M USD
Jan 1, 2021
31.85 M USD
Jan 1, 2022
32.43 M USD
The ViewRay R&D Expenses history
YEARR&D ExpensesYoY
32.43 MUSD+1.83%
31.85 MUSD+27.36%
25.01 MUSD+30.96%
19.10 MUSD+15.59%
16.52 MUSD+12.31%
14.71 MUSD+28.55%
11.44 MUSD+9.50%
10.45 MUSD+11.16%
9.40 MUSD—
Access this data via the Eulerpool API

ViewRay Stock analysis

What does ViewRay do? ViewRay Inc. is an American medical technology company based in Cleveland, Ohio. It was founded in 2004 by Ivor Jankovic and specializes in the manufacturing of radiation therapy devices. The history of ViewRay begins with the idea of developing innovative technology to treat cancer patients more effectively and gently. In 2005, the company entered into an agreement with the Cleveland Clinic Lerner Research Institute to conduct research on a novel magnetic resonance-guided radiation therapy machine. The research project was led by James F. Dempsey, Chair of the Department of Radiation Oncology at the Cleveland Clinic. In 2009, the first magnetic resonance-guided radiation therapy system was delivered and implemented at the Cleveland Clinic. ViewRay's business model is based on the development and manufacturing of innovative medical devices aimed at making the treatment of cancer patients more effective and gentle. The company focuses on combining magnetic resonance imaging (MRI) and radiation therapy to ensure more precise and safer treatment. ViewRay offers various products, including the MRIdian-Linac system, an advanced radiation therapy device that utilizes MRI technology to provide real-time images of the tumor during radiation. This allows for precise targeting of the tumor while sparing the surrounding tissue. The system also offers the ability to sync radiation therapy with the patient's breathing cycle, further improving the accuracy and effectiveness of the treatment. In addition to the MRIdian-Linac system, ViewRay also offers the MRIdian-MRI system, which is solely dedicated to imaging. The MRIdian-MRI is a diagnostic instrument that allows for better visualization of tissue and tumor studies. The system uses the same MRI technology as the MRIdian-Linac to generate radiation-free images. ViewRay has also specialized in the development of software tools that assist doctors in better planning and monitoring radiation therapy. This includes the RayCare Oncology Information System, which provides a comprehensive workflow and management platform, as well as the RayStation Treatment Planning Software, which enables more precise radiation therapy planning. In terms of market reach, ViewRay has a global presence. The company has a strong presence in North America, Europe, and Asia, and works closely with leading research institutes and hospitals to evaluate and improve the effectiveness and efficiency of its technologies. Overall, ViewRay has developed an innovative and unique portfolio of products and solutions that improve radiation therapy and increase accuracy and safety for patients and doctors. The company is a leader in the development of MRI-guided radiation therapy systems and is expected to continue playing a significant role in the medical technology industry in the future. ViewRay is one of the most popular companies on Eulerpool.

Frequently Asked Questions about ViewRay stock

Research & Development Expenses of ViewRay is 32.43 M USD in 2022.

Research & Development Expenses of ViewRay changed from 31.85 M USD to 32.43 M USD, representing a 1.83% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Research & Development Expenses ViewRay since 2006 – with annual values, charts, and detailed analysis.

R&D expenses represent the costs incurred in researching and developing new products, services, or processes. High R&D spending can signal innovation and future growth potential.

Research & Development Expenses's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Research & Development Expenses's ViewRay historically and in real time.

Access this data via the Eulerpool API

Income Statement — ViewRay

All Key Metrics — ViewRay